Your browser doesn't support javascript.
loading
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
Zhao, Jinge; Zhang, Mengni; Liu, Jiandong; Liu, Zhenhua; Shen, Pengfei; Nie, Ling; Guo, Wenhao; Cai, Diming; Liu, Jiyan; Armstrong, Cameron M; Sun, Guangxi; Chen, Junru; Zhu, Sha; Dai, Jindong; Zhang, Haoran; Zhao, Peng; Zhang, Xingming; Yin, Xiaoxue; Zhu, Xudong; Ni, Yuchao; Chen, Ni; Zeng, Hao.
Afiliação
  • Zhao J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang M; Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
  • Liu J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Liu Z; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Shen P; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Nie L; Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
  • Guo W; Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China.
  • Cai D; Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, China.
  • Liu J; Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Armstrong CM; Department of Urology and Comprehensive Cancer Center, University of California Davis, Sacramento, California.
  • Sun G; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Chen J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhu S; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Dai J; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhao P; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhang X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Yin X; Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
  • Zhu X; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Ni Y; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Chen N; Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.
  • Zeng H; Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Prostate ; 79(13): 1553-1562, 2019 09.
Article em En | MEDLINE | ID: mdl-31294486

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração / Membro C3 da Família 1 de alfa-Ceto Redutase / Androstenos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: Prostate Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração / Membro C3 da Família 1 de alfa-Ceto Redutase / Androstenos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Male Idioma: En Revista: Prostate Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos